Nicotinamide Riboside Clinical Trial for GWI
ConditionGulf War Illness
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age47-70
SponsorRoskamp Institute Inc.
About this trial
In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).
Eligibility criteria
Qualifiers
Both sexes, all ethnic groups, and ages 47 to 70 years.
Subject willing and able to give informed consent.
Medically stable as per the investigator's discretion.
Negative urine pregnancy test for females of childbearing potential. A woman is considered of childbearing potential unless she is surgically sterile (hysterectomy or tubal ligation) or is postmenopausal (no menstrual cycle for 2 years or more).
Disqualifiers
Diagnosed by a physician with medical or psychiatric conditions that would account for their symptoms or interfere with their ability to report their symptoms, as per investigator discretion.
Female subject is either pregnant or nursing; or if female subject is of childbearing age is not currently on or is unwilling and/or unable to use birth control.
Have contraindications, allergy, or sensitivity to NR, vitamin B3, or excipients (microcrystalline cellulose, silicon dioxide, magnesium stearate, hypromellose, and/or titanium dioxide).
Any significant medical condition that could interfere with study conduct, as per investigator discretion. These may include but are not limited to the following: untreated chronic hypertension (defined as systolic > 180 mmHg; diastolic >110 mmHg), myocardial infarction within 6 months of screening, renal failure, hepatic failure, and/or receiving chemotherapy.
Trial design
Treatments tested in this trial
- Nicotinamide Riboside
- Placebo
Treatment groups
52 Participants
are divided into 2 treatment groupsSponsors and collaborators
Roskamp Institute Inc.
Lead sponsor
United States Department of Defense
Collaborator
Nova Southeastern University
Collaborator
Source ClinicalTrials.gov